Virtues and pitfalls of EAE for the development of therapies for multiple sclerosis
Virtues and pitfalls of EAE for the development of therapies for multiple sclerosis
复制标题
DOI：
10.1016/j.it.2005.08.014
复制
发表时间：
2005-11-01
影响因子：
16.8
通讯作者：
Zamvil, SS
中科院分区：
文献类型：
--
作者：
Steinman, L;Zamvil, SS
实验性自身免疫性脑脊髓炎（EAE）是一个有用的模型，以帮助开发新的治疗MS。所有治疗MS批准改善EAE。醋酸格拉替雷和那他珠单抗这两种获批药物是直接从EAE研究中开发的。在EAE成功后，MS中的几项试验正在进行中，包括髓鞘的改变肽配体，DNA疫苗和他汀类药物。然而，EAE未能预测某些方法的结果。这里讨论这种失败的原因。
Experimental autoimmune encephalomyelitis (EAE) is a useful model for aiding the development of new treatments for MS. All therapies approved for MS ameliorate EAE. Two approved medications, glatiramer acetate and Natalizumab, were developed directly from studies in EAE. Several trials are ongoing in MS after success in EAE, including altered peptide ligands of myelin, DNA vaccines and statins. However, EAE has failed to predict the outcome of certain approaches. The reasons underlying such failures are discussed here.